摘要
目的:探讨固本防喘胶囊对慢性阻塞性肺疾病(COPD)患者治疗作用的机制。方法:采用双盲随机方法将86例老年COPD急性加重期患者分为治疗组和对照组(各43例),两组基础治疗相同;治疗组加服中药固本防喘胶囊。采用酶联免疫吸附法(ELISA)检测痰中白细胞介素8(IL8)和嗜酸粒细胞趋化因子水平;采用酶标仪检测痰中类糜蛋白酶活性;比较治疗前后上述指标的变化。结果:1治疗组治疗后重、中度患者痰中类糜蛋白酶活性被抑制、IL8和嗜酸粒细胞趋化因子水平均显著降低,痰中中性粒细胞(NEU)和EOS计数亦降低;与治疗前比较差异均有显著性(P均<0.05),与对照组比较差异亦均有显著性(P均<0.05)。2痰类糜蛋白酶活性与IL8、嗜酸粒细胞趋化因子水平和临床症状评分均呈正相关(P均<0.01);IL8水平与痰NEU、EOS计数也均呈正相关(P均<0.05)。结论:固本防喘胶囊对COPD患者嗜酸粒细胞趋化因子、肥大细胞的抑制作用,可能是该方治疗COPD的机制之一。
Objective： To investigate the mechanism of curative effects of Guben Fangchuan capsule （固本防喘胶囊） on chronic obstructive pulmonary disease （COPD）. Methods： Using double blind control method, 86 elderly COPD patients in in acute exacerbating stage were divided into treatment group and control group （n=43 in each group）. The conventional treatment of the two groups was the same. Additionally, the patients in the treatment group were given Guben Fangchuan capsules orally. The levels of interleukin - 8 （IL- 8） and eotaxin in phlegm were detected by enzyme linked immunoadsorbent assay （ELISA）. Chymase activity in phlegm was determined by spectrophotometry. They were compared before and after treatment. Results：①The activity of chymase, the levels of IL -8, eotaxin, neutrophil （NEU） and eosinophil （EOS） in phlegm in patients with intermediate and severe COPD patients were lower after treatment in treatment group than those of the patients before treatment and control group （all P〈0.05）. ②There were positive correlations between chymase and IL - 8, eotaxin, clinical symptom score, as well as IL - 8 and NEU, EOS levels in phlegm of elderly acute COPD patients （all P〈0.05）. Conclusion： Guben Fangchuan capsule can suppress eotaxin, mast cell, and may be one of the main mechanism in treatment of COPD.
出处
《中国中西医结合急救杂志》
CAS
2006年第2期76-79,共4页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
基金
广东省深圳市科技局基金资助项目(200404166)
